for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Crinetics Pharmaceuticals Inc

CRNX.OQ

Latest Trade

15.69USD

Change

-1.33(-7.81%)

Volume

32,040

Today's Range

15.57

 - 

17.04

52 Week Range

10.63

 - 

26.65

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
17.02
Open
17.04
Volume
32,040
3M AVG Volume
4.67
Today's High
17.04
Today's Low
15.57
52 Week High
26.65
52 Week Low
10.63
Shares Out (MIL)
32.88
Market Cap (MIL)
559.68
Forward P/E
-6.52
Dividend (Yield %)
--

Next Event

Crinetics Pharmaceuticals Inc Annual Shareholders Meeting

Latest Developments

More

Crinetics Pharmaceuticals Reports Q2 2020 Financial Results And Provides Corporate Update

Crinetics Pharmaceuticals Reports First Quarter 2020 Financial Results And Provides Corporate Update

Crinetics Pharmaceuticals Prices Public Offering Of 7.15 Mln Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company is focused on the discovery and development of drugs to treat specialty endocrine diseases and endocrine-related tumors. It develops a pipeline of oral nonpeptide chemical entities that target peptide G protein coupled receptors (GPCRs) for the treatment of endocrine diseases. The Company’s lead product candidate is CRN00808 developed for the treatment of acromegaly. It also develops two other product candidates CRN02481 for hyperinsulinemia, and CRN01941 for the treatment of neuroendocrine tumors. CRN02481 and CRN01941 are both oral nonpeptide somastatin receptors that are in the pre-clinical stages of development. The company also conducts research programs on developing nonpeptide products for the treatment of Cushing’s disease.

Industry

Biotechnology & Drugs

Contact Info

10222 Barnes Canyon Rd Bldg 2

SAN DIEGO, CA

92121-2711

United States

+1.858.4506464

https://www.crinetics.com/

Executive Leadership

Wendall Wierenga

Independent Chairman of the Board

R. Scott Struthers

President, Chief Executive Officer, Director

Marc Wilson

Chief Financial Officer

Adriana Cabre

Vice President of Human Resources

Alan Seth Krasner

Chief Medical Officer

Key Stats

1.80 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2018

-2.230

2019

-2.090

2020(E)

-2.450
Price To Earnings (TTM)
--
Price To Sales (TTM)
623.94
Price To Book (MRQ)
2.76
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-35.43
Return on Equity (TTM)
-33.75

Latest News

Latest News

BRIEF-Crinetics Pharmaceuticals Receives Orphan Drug Designation For Paltusotine

* CRINETICS PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FOR PALTUSOTINE FOR THE TREATMENT OF ACROMEGALY Source text for Eikon: Further company coverage:

BRIEF-Crinetics Confirms Completion For Half Of Enrolled Patients In Ongoing Phase 2 Acrobat Edge Clinical Trial For Paltusotine

* CRINETICS PHARMACEUTICALS CONFIRMS COMPLETION FOR HALF OF THE ENROLLED PATIENTS IN THE ONGOING PHASE 2 ACROBAT EDGE CLINICAL TRIAL FOR PALTUSOTINE Source text for Eikon: Further company coverage:

BRIEF-Crinetics Pharmaceuticals Reports First Quarter 2020 Financial Results And Provides Corporate Update

* CRINETICS PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Crinetics Pharmaceuticals Prices Public Offering Of 7.15 Mln Common Stock

* CRINETICS PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Crinetics Pharmaceuticals Announces Proposed Public Offering Of Common Stock

* CRINETICS PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Crinetics Pharmaceuticals Reports Positive Interim Results For Acrobat Edge Phase 2 Trial Of Paltusotine In Acromegaly Patients

* CRINETICS PHARMACEUTICALS REPORTS POSITIVE INTERIM RESULTS FOR THE ACROBAT EDGE PHASE 2 TRIAL OF PALTUSOTINE (CRN00808) IN ACROMEGALY PATIENTS AND PROVIDES CORPORATE UPDATE

BRIEF-Crinetics Pharmaceuticals Reports Q4 Loss Per Share Of $0.60

* CRINETICS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up